Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2014-12-10 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - TECHNOLOGY TRANSFER AGREEMENT WITH ACADEMY OF MILITARY MEDICAL SCIENCES FOR AN INNOVATIVE ANTIDEPRESSANT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding a technology transfer agreement for an innovative antidepressant drug. It is an announcement of a business development event, specifically a technology transfer agreement, and does not contain financial statements, audit information, or regulatory certifications. The document is relatively short (4594 characters) and is an announcement rather than a detailed report or transcript. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Call Transcript. It is not related to board changes, voting results, or share transactions. The content is about a business agreement and technology transfer, which aligns best with a general Regulatory Filing (RNS) as it is a regulatory announcement that does not fit other specific categories.
2014-12-10 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 November 2014
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/11/2014, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content is focused on share capital changes and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting monthly share capital movements, typical for compliance with exchange rules. The document is not an annual or interim report, earnings release, or management discussion. It is a regulatory announcement about share capital movements, fitting best under Regulatory Filings (RNS).
2014-12-03 English
NON-COMPLIANCE WITH RULE 3.10A OF THE LISTING RULES
Board/Management Information Classification · 95% confidence The document is an announcement regarding non-compliance with a listing rule (Rule 3.10A) related to the appointment of an independent non-executive director. It references a previous announcement and states the company's intention to appoint a suitable candidate by a certain date. The content focuses on board composition and compliance with listing rules, which pertains to management or board information. The document is short (1905 characters) and is an announcement rather than a detailed report. Therefore, it fits best under Board/Management Information (MANG).
2014-11-28 English
UNAUDITED RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2014
Interim / Quarterly Report Classification · 95% confidence The document is an unaudited consolidated financial results announcement for the nine months ended 30 September 2014 by CSPC Pharmaceutical Group Limited. It contains detailed financial data including revenue, profit, segment information, earnings per share, and business review. The document is comprehensive and includes actual financial statements and substantive financial data for a period shorter than a full fiscal year (nine months). It is not a full annual report but an interim/quarterly report covering a partial fiscal year period. The document is not merely an announcement of a report or a certification, but contains detailed financial results and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2014
2014-11-25 English
VOLUNTARY ANNOUNCEMENT - THE GROUP'S PRODUCTION WORKSHOPS FOR CEPHALOSPORIN PRODUCTS PASSED ONSITE INSPECTION BY THE U.S. FDA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the passing of a U.S. FDA onsite inspection for their production workshops. It is an announcement of a regulatory milestone and product quality achievement, not a financial report or detailed regulatory filing. The document is relatively short (3711 characters) and does not contain financial data, management discussion, or detailed report content. It is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial or governance report. It is also not a certification or voting result. The content fits best under a general regulatory announcement category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2014-11-17 English
VOLUNTARY ANNOUNCEMENT - SUBMISSION OF CLINICAL STUDY APPLICATION TO THE CENTER FOR DRUG EVALUATION FOR THE GROUP'S HEPATITIS C DRUG "SOFOSBUVIR TABLET"
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the submission of a clinical study application for a hepatitis C drug to a regulatory authority. It is an announcement about a regulatory or development milestone rather than a financial report or detailed corporate filing. The document is relatively short (3639 characters) and does not contain financial data, management discussion, or detailed report content. It is not an earnings release, annual report, or any form of financial or governance report. It is also not a regulatory certification or officer attestation. The content fits best as a general regulatory announcement or compliance-related disclosure. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2014-11-17 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.